Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: Computational modelling and preliminary in vivovalidation

10.1126/science.1095833

Matsumura Y, 1986, Cancer Res, 46, 6387

Poon RT, A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver

Celsion. A, phase III, randomized, double-blinded, dummy-controlled study of the efficacy and safety of ThermoDox® (thermally sensitive liposomal doxorubicin) in combination with radiofrequency ablation (RFA) compared to RFA-alone in the treatment of non-resectable hepatocellular carcinoma. Clinical trial

National Cancer Institute. A phase I dose escalation study of heat activated liposome delivery of doxorubicin and radiofrequency ablation of primary and metastatic tumors of the liver. Clinical trial. National Institutes of Health.

Duke University Cancer Institute and National Cancer Institute. A phase I, dose escalation and pharmacokinetics study of temperature sensitive liposome encapsulated doxorubicin (ThermoDox™) and hyperthermia in patients with local-regionally recurrent breast cancer. Clinical trial. National Institutes of Health.

10.1517/14656560802677874

10.1126/science.364652

10.1016/0277-5379(91)90274-H

10.1023/A:1016206631006

Kong G, 2000, Cancer Res, 60, 6950

10.1016/S0169-409X(01)00233-2

10.1016/j.jconrel.2010.01.006

Kong G, 2001, Cancer Res, 61, 3027

10.1016/j.bbamem.2007.05.021

10.3109/02656731003623590

10.3109/02656736.2010.528140

Rumboldt Z, 2005, Am J Neuroradiol, 26, 1178

10.1002/jmri.21429

10.1007/s10439-009-9645-x

10.1109/TMI.2006.873296

10.1080/02656730601186138

10.1109/MPUL.2011.942604

10.1148/radiol.11100155

10.1158/1078-0432.CCR-06-2443

10.3109/02656736.2010.518198

10.1016/j.jconrel.2010.10.036

Gasselhuber A, 2011, Proc SPIE, 7901, 7910F

10.1016/j.jconrel.2011.12.011

10.1615/CritRevBiomedEng.v25.i6.20

10.1038/sj.neo.7900096

10.1115/1.3072952

10.1152/jappl.1948.1.2.93

10.1063/1.3131434

10.1002/mrm.1910340606

10.3109/02656739209037988

10.1007/s10439-007-9300-3

10.1016/B978-0-12-222800-1.50010-3

10.2214/ajr.176.3.1760667

10.1002/jps.10161

10.1593/neo.05118

10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S

10.1016/0360-3016(93)90348-Y

10.1200/JCO.1999.17.3.880

10.1006/jtbi.2003.3156

10.1177/074823379701300401

10.1006/mvre.1993.1024

Jain RK, 1987, Cancer Res, 47, 3039

10.1016/S0168-3659(03)00237-2

10.1016/0006-2952(86)90195-4

10.3109/02656736.2012.680173

10.1080/02656730802064621

10.1002/mrm.21887

10.1002/(SICI)1097-0142(19970115)79:2<214::AID-CNCR3>3.0.CO;2-K

10.1148/radiology.220.2.r01au44420